Simplexa COVID-19 Direct
FDA 510(k) clearance K212147 · decided 2022-09-13
Clearance details
- K-number
- K212147
- Device name
- Simplexa COVID-19 Direct
- Applicant
- Diasorin Molecular, LLC
- Decision
- Substantially Equivalent
- Date received
- 2021-07-09
- Decision date
- 2022-09-13
- Days to decision
- 431 days
- Clearance type
- Traditional
- Product code
- QQX
- Device class
- 2
- Regulation number
- 866.3981
- Medical specialty
- Microbiology
- Advisory committee
- Microbiology
- Location
- Cypress, CA, US
- Third-party review
- No
- Expedited review
- No
+ Add to Predicate Builder ◉ Watch Diasorin Molecular
Need this as data, not a web page?
Query all 176,000+ clearances through the Atlas FDA API, or subscribe to weekly change alerts. Self-serve from $29/mo.
Similar devices under this product code
Devices cleared under the same product code - the starting set for predicate research.
| Record | Firm | Date |
|---|---|---|
| Aptima SARS-CoV-2 Assay (K243396) | Hologic, Inc. | 2025-02-13 |
| cobas® SARS-CoV-2 Qualitative for use on the cobas® 5800/6800/8800 Systems (K240867) | Roche Molecular Systems, Inc. | 2025-02-11 |
| Xpert® Xpress CoV-2 plus (XPRS-COV2-10) (K242109) | Cepheid® | 2025-01-15 |
| Alinity m SARS-CoV-2 AMP Kit (09N78-096); Alinity m SARS-CoV-2 CTRL Kit (09N78-086) (K241580) | Abbott Molecular | 2024-12-06 |
| Applied Biosystems™ TaqPath™ COVID-19 Diagnostic PCR Kit (K233453) | Life Technologies Corporation | 2024-07-10 |
| Xpert® Xpress CoV-2 plus (K230440) | Cepheid® | 2023-10-13 |
| cobas SARS-CoV-2 Qualitative for use on the cobas 5800/6800/8800 Systems (K231306) | Roche Molecular Systems, Inc. | 2023-06-01 |
| cobas SARS-CoV-2 Qualitative for use on the cobas 6800/8800 Systems (K213804) | Roche Molecular Systems, Inc. | 2022-10-22 |
| BioFire COVID-19 Test 2 (K221460) | Biofire Defense, LLC | 2022-07-25 |
| BioFire COVID-19 Test 2 (K211079) | Biofire Defense, LLC | 2021-11-01 |
Recalls involving this device
No recalls on record reference this clearance.